DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Dry and Wet Age-Related Macular Degeneration – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AMD patient populations covering 171 countries and more than 99% of…
Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Edema | US | 2022
MARKET OUTLOOK Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative,…
Dry and Wet Age-Related Macular Degeneration | Disease Landscape & Forecast | G7 | 2021
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Edema | US | 2021
MARKET OUTLOOK Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative,…
Dry and Wet Age-Related Macular Degeneration | Special Topics | Beovu: Nine Months Postlaunch for Wet AMD | US | 2020
Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
Dry and Wet Age-Related Macular Degeneration | Special Topics | Beovu: Three Months Postlaunch for Wet AMD | US | 2020
Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
Special Focus on Retinal Therapies: Payer Management of the Medical Benefit | Access & Reimbursement | US | 2019
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Edema | US | 2019
The wet age-related macular degeneration (AMD) market in the United States is unique in that it is dominated by Genentech’s Avastin, an oncology drug that is used off-label to treat wet AMD,…
